EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans

Donghui Liu, Qian Li, Shu Yan, Xinyue Zhang, Weiqiang Li, Feiyu Wang, Lei Gao, Fei Geng, Haiyan Zhou, Panpan Ye, Furong Zhao, Weizhe Xue und 3 weitere

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-024-04744-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Donghui Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. Hauptthemen laut MEDLINE: ErbB Receptors, Protein Kinase Inhibitors, Carbon Radioisotopes, Feces. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Key Technologies R&D Program of Guangdong Province, National Key R&D Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsProtein Kinase InhibitorsCarbon RadioisotopesFecesHumansMaleAdultTandem Mass SpectrometryAntineoplastic AgentsYoung Adult

Stichwörter der Autor:innen

EGFR-TKIMass balancePLB1004Radioactivity[14C]PLB1004

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsCarbon RadioisotopesEGFR protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
  • Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China.
  • Department of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Engineering and Technology Research Center for Pediatric Drug Devel…
  • Beijing Avistone Biotechnology Co., Ltd, Beijing, 100102, China.
  • School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210023, China. xxdiao@simm.ac.cn.
  • Shanghai Center for Drug Metabolism and Pharmacokinetics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201210, China. xxdiao@simm.ac.cn.

Förderung

  • National Natural Science Foundation of China
  • Key Technologies R&D Program of Guangdong Province
  • National Key R&D Program of China

Zitieren

APA

Liu, D., Li, Q., Yan, S., Zhang, X., Li, W., Wang, F., Gao, L., Geng, F., Zhou, H., Ye, P., Zhao, F., Xue, W., Zhang, P., Diao, X., & Zhao, W. (2025). Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04744-7

Vancouver

Liu D, Li Q, Yan S, Zhang X, Li W, Wang F, et al. Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-024-04744-7

BibTeX
@article{Liu2025,
  author = {Liu, Donghui and Li, Qian and Yan, Shu and Zhang, Xinyue and Li, Weiqiang and Wang, Feiyu and Gao, Lei and Geng, Fei and Zhou, Haiyan and Ye, Panpan and Zhao, Furong and Xue, Weizhe and Zhang, Peilong and Diao, Xingxing and Zhao, Wei},
  title = {Pharmacokinetics, mass balance, and metabolism of [14C]PLB1004, a selective and irreversible EGFR-TKI in humans},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-024-04744-7}
}
Kostenlos starten →